Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 11, 2003, Pages 3651-3652

  Howe, Robin A ^a,b   Wootton, Mandy ^a,b   Noel, Alan R ^a   Bowker, Karen E ^a   Walsh, Timothy R ^b   MacGowan, Alasdair P ^a,b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b Dept Anat Sch Med Sci U   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; POSIZOLID; RIFAMPICIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 0242322571     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.11.3651-3652.2003     Document Type: Article

References (10)

1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2002. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob. Agents Chemother. 46:2662-2664.
2. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.
3. Johnson, A. P., M. Warner, and D. M. Livermore. 2002. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. J. Antimicrob. Chemother. 50:89-93.
4. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
5. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial susceptibility testing. Document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
6. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
7. Walsh, T. R., and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56: 657-675.
8. Wilson, P., J. A. Andrews, R. Charlesworth, R. Walesby, M. Singer, D. J. Farrell, and M. Robbins. 2003. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51:186-188.
9. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.
10. Xiong, L., P. Kloss, S. Douthwaite, N. M. Andersen, S. Swaney, D. L. Shinabarger, and A. S. Mankin. 2000. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J. Bacteriol. 182:5325-5331.